Physician profile
Oscar Murillo
NPI 1205809241
$3,305.72
in general payments reported to CMS, 2019-2025
10 companies · $485 in 2025
The $485 reported for 2025 was more than what 78% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $360 · 2021: $449 · 2022: $697 · 2023: $125 · 2024: $255 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,129.33 | 2019-2022 | |
| Amgen INC. | $793.35 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $408.34 | 2022-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.14 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $212.98 | 2020-2025 | Wainua |
| Medtronic, INC. | $141.62 | 2024 | Minimed 780g |
| Pfizer INC. | $124.74 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $114.48 | 2021 | |
| Avanir Pharmaceuticals, INC. | $18.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Murillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.